Orexo nabs regulatory win for fast-dissolving opioid dependence therapy

by

Call 1 (888) 460-6556 to speak with a counselor.

Orexo (STO:ORX) said today that the European Medicines Agency granted marketing authorization for its Zubsolv rapidly-disintegrating treatment for opioid dependence.
The buprenorphine and naloxone sublingual tablet is the first to be approved in Europe with six different strengths, according to the Sweden-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post Orexo nabs regulatory win for fast-dissolving opioid dependence therapy appeared first on MassDevice. (Source: Mass Device)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Previous post:

Next post: